Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
Immune checkpoint inhibition has transformed cancer treatment. For gastroesophageal cancer, this class of drugs have demonstrated durable responses and survival benefit in a subgroup of patients, resulting in regulatory approval. However, several recent randomized phase III studies in gastroesophage...
Main Authors: | Raghav Sundar, Elizabeth C. Smyth, Siyu Peng, Joe P. S. Yeong, Patrick Tan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00763/full |
Similar Items
-
Efficacy of immune‐checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta‐analysis
by: Yulia Kundel, et al.
Published: (2020-10-01) -
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials
by: Anwaar Saeed, et al.
Published: (2021-01-01) -
Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach
by: Jin-On Jung, et al.
Published: (2020-01-01) -
Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing
by: Gianluca Lopez, et al.
Published: (2020-09-01) -
Immunotherapy for Gastroesophageal Cancer
by: Emily F. Goode, et al.
Published: (2016-09-01)